A new item has been added to the shopping cart


Tell to a friend

Your Name:
E-mail of your friend:
Captcha CAPTCHA code
Enter the text in the image above


Already a subscriber? Log in now for online Access.


Artículo Tomo 71, Número. 4, Mayo 2018

Archivos Españoles de Urología

Therapetic options after BCG failure.

Authors: Andrea Sánchez Vázquez, José Gregorio Pereira Arias, Mikel Gamarra Quintanilla, Felipe Urdaneta Salegui, Jorge Mora Christian, Gaspar Ibarluzea González y Ander Astobieta Odriozola.

Arch. Esp. Urol. 2018; 71 (4): 349-357 Keywords: N

Vol. 71, Number. 4, May 2018

Bladder cancer is the 9th most prevalent cancer in the world. It is divided into muscle invasive bladder cancer (MIBC) and non muscle invasive bladder cancer (NMIBC). Over 75% belong to the second group and it will be classified according to the risk of progression and recurrence. In high and intermediate risk tumors. There is indication for the use of bladder instillations with BCG as it reduces the number of recurrences and disease progression to MIBC. In spite of this, disease control is not possible in all cases and there could be recurrence or progression of the disease to MIBC. This article is a review of the therapeutic options of tumor recurrence after failure of BCG treatment.

Only subscribers

Copyright © 2015 | Valid support N°12/08-W-CM | ISSN-ONLINE: 1576-8260 |